OncoResponse Email Format
Research ServicesTexas, United States11-50 Employees
OncoResponse is a clinical-stage, privately held biotechnology company focused on immuno-oncology. It develops cancer therapies by studying the immune systems of elite cancer responders to identify novel antibodies and targets within the tumor microenvironment. The company relies on a proprietary B-cell discovery platform and has established a strategic alliance with MD Anderson Cancer Center to advance therapeutics through collaboration with academia and industry. Its lead program, OR2805, has entered clinical testing, reflecting its distinctive approach to advancing cancer treatments. The company is based in Houston, Texas, and Seattle, Washington, and operates with a small to mid-sized team. In November 2023, OncoResponse announced the launch of two antibodies, OR502 and OR641, along with preclinical data presented at SITC 2023.